CRISPR Therapeutics AG is advancing CTX120, an allogeneic CRISPR-Cas9-engineered T cell therapy targeting BCMA, for the treatment of relapsed or refractory multiple myeloma. The therapy is positioned within a competitive landscape that includes CAR T-cell therapies and other BCMA-targeted treatments. Given the increasing prevalence of multiple myeloma and the limitations of existing therapies, CTX120 has the potential to capture significant market share, particularly if it demonstrates a favorable safety and efficacy profile. The termination of the trial indicates a strategic pivot to follow-up studies, suggesting ongoing commitment to this asset's development and potential future commercialization.